NASDAQ$MNKD

MannKind Corp · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

Reported financial results for the fourth quarter and full year ended December 31, 2021.

MannKind Corporation reported a solid fourth quarter with Afrezza net revenue hitting a record $11.3 million, and the company ended the year with over $260 million in cash and investments. Total revenues were $12.5 million, with Afrezza net revenue contributing $11.3 million and collaborations and services revenue contributing $1.2 million. The net loss for the quarter was $28.1 million, or $0.11 per share.

  • Afrezza net revenue reached a record $11.3 million in Q4 2021, a 13% increase compared to Q4 2020.
  • Total revenues for Q4 2021 were $12.5 million, including $11.3 million from Afrezza and $1.2 million from collaborations and services.
  • The company had over $260 million in cash and investments at the end of 2021.
  • Net loss for Q4 2021 was $28.1 million, or $0.11 per share.

Headline financials

Total Revenue

$12.5M

Previous: $18.4M-32.1%
EPS (adj)

-$0.11

Previous: -$0.06-83.3%
Capital Expenditures

$5.19M

Previous: $497K+944.3%
Free Cash Flow

-$17.5M

Previous: -$262K-6593.5%
Net Income

-$28.1M

Previous: -$26.4M-6.2%
Operating Income

-$24M

Previous: -$23.7M-0.9%
Gross Profit

$7.05M

Previous: $6.41M+9.9%
Cash & Equivalents

$124M

Previous: $67M+85.3%
Total Assets

$321M

Previous: $109M+195.7%
Stock-Based Comp

$3.16M

Previous: $1.9M+66.0%

Revenue & EPS history

MannKind · Revenue · Quarterly

$12.5M

Q4 2021-32.1%vs Q4 2020
Beat estimate in 11 of 16 quarters(69%)
ActualEstimate

Revenue by segment

MannKind · $12.5M total across 2 segments · Q4 2021

  • Afrezza
    $11.3M
  • Collaborations and services
    $1.18M-86.0%

Forward guidance

MannKind is focused on commercial growth, pipeline advancement, and managing cash resources.

Tailwinds

  • Future commercial growth
  • Pipeline advancement
  • Ability to commercialize pharmaceutical products
  • Solid cash position
  • Focus on inhaled therapeutic products

Headwinds

  • Risks associated with product commercialization
  • Risks associated with developing product candidates
  • Risks associated with MannKind’s ability to manage its existing cash resources or raise additional cash resources
  • Impact of the COVID-19 pandemic
  • Stock price volatility

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

-0.4%

Avg return

Earnings day

-0.7%

Avg return

5 days after

+1.5%

Avg return

30 days after

39%

25 / 64 earnings

Positive

+44.9%

Q3 2016

Best reaction

-28.5%

Q1 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+24.5%+17.5%+18.5%
Q4 2025-6.9%-16.3%-34.9%
Q3 2025+10.6%-1.1%+3.6%
Q1 2025-4.5%-2.7%-9.7%
Q4 2024-4.4%-5.9%-8.0%
Q3 2024-1.2%-4.8%-8.6%
Q2 2024-1.5%-1.5%+12.5%
Q1 2024-3.6%-1.3%+4.5%
Q4 2023+9.5%+25.7%+26.5%
Q3 2023-0.8%-6.8%-0.3%
Q2 2023+15.5%+11.2%-3.8%
Q1 2023+13.4%+9.0%+6.2%
Q4 2022+4.2%+1.7%-23.1%
Q3 2022+6.3%+20.7%+32.8%
Q2 2022-1.4%-4.6%-9.0%
Q1 2022-8.7%-8.7%+42.7%
Q4 2021-25.7%-24.9%-5.2%
Q3 2021-0.6%+3.1%-14.3%
Q2 2021+5.1%+5.4%+20.8%
Q1 2021-8.4%-3.9%-8.0%
Q4 2020-4.5%-36.8%-40.0%
Q3 2020+8.8%+19.0%+43.9%
Q2 2020+0.0%-4.2%-1.2%
Q1 2020-2.2%-0.7%+4.5%
Q4 2019-7.9%-16.4%-27.6%
Q3 2019-15.1%-16.8%-18.8%
Q2 2019-0.9%+4.6%+13.9%
Q1 2019-12.3%-19.4%-25.2%
Q4 2018+23.8%+17.2%+27.8%
Q3 2018+0.0%-1.1%-2.7%
Q2 2018-26.8%-29.3%-29.9%
Q1 2018+2.3%+8.7%+13.3%
Q4 2017-10.4%-13.5%-30.3%
Q3 2017-7.1%+0.3%-4.3%
Q2 2017-5.7%-2.5%+61.5%
Q1 2017+13.8%-5.4%+39.3%
Q4 2016+9.9%+2.5%-34.2%
Q3 2016+44.9%+51.2%+51.2%
Q2 2016-6.2%+2.0%-27.6%
Q1 2016-28.5%
Q4 2015+6.0%
Q3 2015-19.9%
Q2 2015+4.5%
Q1 2015-8.4%
Q4 2014+2.8%
Q3 2014-1.5%
Q2 2014-8.0%
Q1 2014+5.8%
Q4 2013+5.9%
Q3 2013+7.3%
Q2 2013-5.1%
Q1 2013+11.0%
Q4 2012-1.9%
Q3 2012+2.6%
Q2 2012+3.9%
Q1 2012-8.3%
Q4 2011+7.9%
Q3 2011-1.6%
Q2 2011-10.1%
Q1 2011-11.8%
Q4 2010-5.5%
Q3 2010-2.3%
Q2 2010-0.7%
Q1 2010+3.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro